NDP Condemns Federal Government's Indifference to Pharmacare Recommendations

NDP interim leader Don Davies has labeled the federal government’s reaction to a national pharmacare report as “shockingly dismissive,” calling for greater clarity on the program’s trajectory.

Having played a significant role in negotiating the Pharmacare Act last year, Davies criticized the government’s attitude as politically misleading. This legislation, passed over a year ago, established an expert committee tasked with formulating a universal, single-payer pharmacare model as part of a supply-and-confidence agreement with the Liberals under former Prime Minister Justin Trudeau.

The committee's findings, submitted to Health Minister Marjorie Michel in October and made public last month, urged Ottawa to fund a comprehensive list of essential medications covering over 90% of prescriptions through an independent body, enabling Canadians to access medicines without cost via their health cards.

Additionally, the report advocated for expedited action by circumventing protracted bilateral discussions with provincial and territorial governments, and for enacting legislation to guarantee access to essential medicines.

When queried about the implementation of these recommendations, Michel indicated that the government is reviewing the report yet did not promise any decisive action. She stated, “Independent expert panels have their views, but these are non-binding for the government,” highlighting her role in negotiations with provinces and territories, which dismisses the notion of unilateral moves.

Davies responded sharply to this stance, suggesting that the government may have dismissed the report prior to its careful examination. He noted that committee members and other stakeholders have struggled to arrange a meeting with the health minister since the report's publication.

Committee chair Dr. Nav Persaud emphasized the growing necessity for pharmacare, warning that international trade pressures could affect employment, insurance, and drug prices. Committee member Amy Lamb described the report as a “nation-building investment” in line with Canadian values.

Moreover, Davies urged the government to uphold the Pharmacare Act by moving forward on the initial phase, which relates to negotiating agreements for contraceptives and select diabetes medications. So far, only four agreements have been finalized with B.C., Manitoba, P.E.I., and Yukon, resulting in an inconsistent system deemed inequitable by health advocates.

Davies remarked, “The government claims to support public access to medications but falters when substantial action is necessary.”

Despite promises made during the campaign to safeguard programs like pharmacare, the government’s first budget under Prime Minister Mark Carney revealed no new funding beyond the previously allocated $1.5 billion for 2024, much of which is already tied to existing agreements. The committee estimates the funding needed for the essential medications list ranges from $6–10 billion yearly but anticipates net costs nearing $3 billion due to potential savings from competitive purchasing and current coverage.